Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.58 |
| ▸ | PRKCB | P05771 | 5/20 | 0.58 |
| ▸ | PRKCA | P17252 | 5/20 | 0.58 |
| ▸ | PRKCH | P24723 | 4/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.58 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | PRKACA | P17612 | 2/20 | 0.58 |
| ▸ | PRKACG | P22612 | 2/20 | 0.58 |
| ▸ | PRKACB | P22694 | 2/20 | 0.58 |
| ▸ | CCND1 | P24385 | 2/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | PRKCG | P05129 | 2/20 | 0.58 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30999985 | 0.78 | GSK3B (0.81) | GSK3BGSK3A | |
| Ro-316233 SCHEMBL29373011 | 0.76 | PRKCB (1.00) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| Ro-316233 SCHEMBL624896 | 0.76 | PRKCB (1.00) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL6586836 | 0.75 | GSK3B (1.00) | GSK3BGSK3ACDK2CCNB2CDK1 | |
| SCHEMBL13917970 | 0.75 | PRKCB (0.78) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL2343710 | 0.74 | CDK4 (0.63) | GSK3BGSK3ACAMK2DPRKCBPRKCA | |
| SCHEMBL30999951 | 0.74 | GSK3B (1.00) | GSK3BGSK3A | |
| SCHEMBL6758855 | 0.73 | CAMK2D (0.57) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL3908534 | 0.72 | PRKCB (0.78) | GSK3BCAMK2DPRKCBPRKCAPRKCH | |
| SCHEMBL16939750 | 0.72 | PRKCB (0.67) | GSK3BCAMK2DPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199835-A1 | Neuroprotective and anti-proliferative compounds | AEGERA THERAPEUTICS, INC. (CA) | 2006-09-07 | — | — | US | disclosed |
| US-6960595-B2 | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005014584-A8 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005014584-A9 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005014584-A9 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC (CA) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005014584-A1 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014584-A1 | 3-(INDOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES,3-(BENZIMIDAZOL-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES, AND 3-(INDOLIN-1-YL)-4-(INDOL-3-YL)-PYRROLE-2,5-DIONES; THEIR PREPARATION AND USE AS MODULATORS OF APOPTOSIS | AEGERA THERAPEUTICS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199835-A1 | Neuroprotective and anti-proliferative compounds | MKI67, NES, BCL2A1 | GSK3B 1153/4885GSK3A 1394/4885CAMK2D 2375/4885 |
| US-20030018023-A1 | 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors | HABP2, SERPINC1, F7 | GSK3B 2230/4885GSK3A 2654/4885CAMK2D 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.